EndophthalmitisMANAGEMENT

OPHTHALMOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

532 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Acute angle-closure glaucoma Central retinal artery occlusion Central Retinal Vein Occlusion Chemical eye injury Corneal abrasion Corneal ulcer Endophthalmitis Globe rupture Herpes zoster ophthalmicus Hyphema Iritis-Uveitis Ocular foreign body Optic Neuritis Orbital cellulitis Orbital Floor Fracture (Blowout)Posterior vitreous detachment Retinal detachment Retrobulbar hematoma and orbital compartment syndrome Vitreous Hemorrhage

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp39

Time-critical priorities

›Same-hour recognition and action

›Red painful eye after intraocular procedure or trauma

›Pain out of proportion to external exam

›Vision loss out of proportion to external exam

›Hypopyon on exam

›Layered white cell debris in anterior chamber

›Treat as endophthalmitis until proven otherwise

›Emergent ophthalmology involvement

›ED role is recognition and immediate referral, not definitive treatment

›Definitive treatment is vitreous tap and intravitreal antibiotics or vitrectomy, not an ED procedure

›Do not discharge on topical antibiotics alone

›Topical therapy does not achieve therapeutic intravitreal concentration

›Recognized route to permanent vision loss

›Septic patient with red painful eye

›Endogenous source concern

›Missed presentation pattern in bacteremic or fungemic patients

Immediate consultations

›Specialist activation

›Ophthalmology emergent

›Any hypopyon

›Any suspected endophthalmitis regardless of category

›Infectious diseases for endogenous source

›Organism-directed systemic therapy

›Source control coordination

›Cardiology for endocarditis concern

›Echocardiography interpretation

›Valve surgery planning if indicated

02History/hx55

Presentation pattern

›Symptom cluster

›Eye pain

›Pain out of proportion to external findings

›Worsening despite analgesia

›Vision loss

›Rapid onset over hours to days

›Pain-out-of-proportion and vision-loss pattern together

›Redness and discharge

›Conjunctival injection

›Purulent discharge

›Photophobia

›Anterior chamber inflammation

›Ciliary spasm

Post-operative timeline and category

›Post-cataract and other intraocular surgery timeline

›Acute post-operative onset

›Onset 1 to 7 days after cataract surgery

›Peak onset day 3 to 5 after cataract surgery

›Delayed post-operative onset

›Onset 6 weeks or more after surgery

›Smoldering low-grade course rather than acute pain

›Surgical detail history

›Intraocular lens implantation

›Intraoperative complication or vitreous loss

Post-injection, bleb, and traumatic context

›Category-specific triggers

›Intravitreal injection history

03Physical Exam/exam61

Anterior segment findings

›Anterior chamber and surface findings

›Hypopyon

›Layered white cells in anterior chamber

›Height correlates with severity

›Anterior chamber cell and flare

›Marked inflammatory reaction

›Fibrin formation

›Conjunctival injection and chemosis

›Circumlimbal predominance

›Lid edema

›Corneal edema

›Endothelial decompensation from inflammation

›Reduced view to posterior segment

Posterior segment and vision findings

›Vision and fundus findings

›Visual acuity

›Marked reduction from baseline

›Documented for vitrectomy versus tap-and-inject decision

›Poor or absent red reflex

›Vitreous haze or debris

›Fundus view obscured

›Relative afferent pupillary defect

›Optic nerve or severe retinal involvement

›Poor prognostic marker

›Vitritis on available view

›Snowball or fluff-ball opacities

›Correlates with organism virulence

04Differential Diagnosis/ddx44

Infectious endophthalmitis categories

›Endophthalmitis by mechanism

›Acute post-operative endophthalmitis

›Onset 1 to 7 days after cataract surgery

›Coagulase-negative staphylococci most common organism

›Delayed post-operative endophthalmitis

›Onset 6 weeks or more after surgery

›Cutibacterium acnes or fungal organisms characteristic

›Post-intravitreal-injection endophthalmitis

›Onset within days of injection

›Low per-injection incidence, cumulative risk with repeated injections

›Bleb-associated endophthalmitis

›Can occur years after glaucoma surgery

›Streptococcus and Haemophilus species more virulent, poorer visual prognosis

›Post-traumatic endophthalmitis

›Open globe injury, especially with retained intraocular foreign body

›Bacillus species and fungal organisms with organic contamination

›Endogenous endophthalmitis

›Hematogenous seeding from systemic infection

›Gram-negative organisms and Candida species more common than in exogenous categories

Noninfectious mimics

›Alternative etiologies

›Toxic anterior segment syndrome

›Onset within 12 to 48 hours after anterior segment surgery, faster than typical infectious onset

›Diffuse corneal edema with minimal to no vitritis, responds to topical steroids rather than intravitreal antibiotics

›Retained lens fragment inflammation

›Post-cataract surgery

›Sterile inflammatory reaction without organism

05Laboratory Tests/lt36

Vitreous and aqueous studies

›Intraocular specimen testing

›Vitreous tap for gram stain and culture

›Obtained at time of intravitreal antibiotic injection

›Aerobic, anaerobic, and fungal culture media

›Aqueous tap as adjunct

›Lower yield than vitreous specimen

›Used when vitreous sampling delayed

›Vitreous PCR broad-range testing

›Higher sensitivity than culture in some series

›False negative risk after prior antibiotic exposure

Systemic and endogenous source labs

›Source-directed testing

›Blood cultures times two

›Drawn before systemic antibiotics when feasible

›Central to endogenous source confirmation

›Complete blood count

›Leukocytosis support

›Not required for diagnosis

›Inflammatory markers

›C-reactive protein trend

›Erythrocyte sedimentation rate trend

›Blood glucose and HbA1c

›Diabetes screening in new endogenous presentations

›Blood glucose in mmol/L

›Renal function

›Aminoglycoside and vancomycin dosing safety

›Baseline before nephrotoxic systemic antifungal therapy

06Diagnostic Tests/dt47

Scoring Systems

›Prognostic and diagnostic frameworks

›Endophthalmitis Vitrectomy Study visual acuity stratification

›Presenting visual acuity of light perception only

›Presenting visual acuity of hand motions or better

›Stratification drives vitrectomy versus tap-and-inject decision

›Modified Duke criteria for infective endocarditis

›Applied when endogenous source suspected

›Combines blood culture, echocardiographic, and clinical criteria

MRI

›MRI considerations

›Limited acute role

›Not first-line for suspected endophthalmitis

›Time delay disadvantage in a same-hour emergency

›Avoidance with suspected metallic intraocular foreign body

›Migration risk

›Tissue injury risk

›Selective use

›Orbital or intracranial extension concern

›Suspected septic cavernous sinus involvement

›CT orbit and source imaging

›Orbit and sinus CT with contrast

›Post-traumatic retained foreign body localization

›Concurrent orbital cellulitis or extension concern

›Abdominal or hepatobiliary CT

›Hepatobiliary source suspected in endogenous disease

›Liver abscess identification

07Disposition/dispo30

Level of care and admission

›Admission pathway

›Inpatient admission default

›Need for intravitreal therapy and close ophthalmology follow-up

›Systemic infection requiring IV therapy in endogenous cases

›ICU triggers

›Septic shock in endogenous disease

›Hemodynamic instability

›Transfer criteria

›No ophthalmology coverage capable of same-hour tap and injection

›No vitrectomy capability when indicated

Vitrectomy versus tap-and-inject decision

›Endophthalmitis Vitrectomy Study-derived pathway

›Presenting visual acuity of hand motions or better

›Vitreous tap and intravitreal antibiotics equivalent to immediate vitrectomy

›Vitrectomy reserved for failure of initial therapy

›Presenting visual acuity of light perception only

›Immediate pars plana vitrectomy favored

›Improved outcomes over tap alone in this subgroup

›Therapy not working

›Worsening pain, vision, or hypopyon 24 to 48 hours after tap and injection

›Repeat tap and injection or escalate to vitrectomy, reconsider fungal or resistant organism

Endogenous-specific disposition and transfer

›Source control and specialist coordination

›Admission with infectious diseases co-management

›Organism-directed systemic therapy duration

›Source control procedure planning

›Cardiology and cardiac surgery involvement

08Treatment/t102

Vitreous tap and intravitreal antibiotics

›Ophthalmology-performed intraocular therapy

›Vitreous tap and specimen collection

›Performed at bedside or in procedure suite by ophthalmology

›Specimen sent before intravitreal antibiotic administration

›Standard empiric intravitreal regimen

›Vancomycin intravitreal 1 mg/0.1 mL

›Gram-positive coverage including coagulase-negative staphylococci

›Maximum single intravitreal volume 0.1 mL per agent to limit retinal toxicity

›Ceftazidime intravitreal 2.25 mg/0.1 mL

›Gram-negative coverage

›Repeat injection considered if no improvement at 48 to 72 hours

›Topical antibiotics as adjunct only, never as sole therapy

›Moxifloxacin ophthalmic 0.5% one drop every 1 to 2 hours while awake

›Surface adjunct only, does not substitute for intravitreal therapy

›Does not achieve therapeutic vitreous concentration

›Explicit statement that topical antibiotics alone are inadequate treatment for endophthalmitis

Systemic antibiotics

›Where systemic therapy does and does not help

›Exogenous post-operative and post-injection categories

›Endophthalmitis Vitrectomy Study found no added benefit from systemic antibiotics amikacin and ceftazidime in postoperative bacterial endophthalmitis

›Intravitreal therapy remains the primary treatment in these categories

›Endogenous category

›Systemic antibiotics essential, directed at the bacteremic or fungemic source

›Empiric vancomycin IV 15 to 20 mg/kg every 8 to 12 hours plus ceftazidime IV 2 g every 8 hours pending culture

›Narrow to organism once identified

›Renal dosing adjustment for both agents

›Post-traumatic category

›Systemic antibiotics at time of globe repair for contamination and endophthalmitis prophylaxis

›Coverage includes gram-positive, gram-negative, and organic contamination risk

Antifungal therapy

›Fungal coverage

›Suspicion triggers

›Delayed post-operative presentation

›Endogenous disease with intravenous drug use, prolonged IV access, or total parenteral nutrition

›Intravitreal antifungal

›Amphotericin B intravitreal 5 to 10 mcg/0.1 mL

›Reserved for confirmed or strongly suspected fungal etiology

›Ophthalmology-administered

›Voriconazole intravitreal 100 mcg/0.1 mL

›Alternative or adjunct agent

›Broader mold coverage than amphotericin B

›Systemic antifungal for endogenous candidemia source

›Fluconazole IV or PO 800 mg loading then 400 mg daily

›Adjust for renal function

›Duration guided by infectious diseases

›Liposomal amphotericin B IV 3 to 5 mg/kg daily for non-fluconazole-susceptible organisms

›Nephrotoxicity and electrolyte monitoring

›Infusion-related reaction monitoring

Steroids

›Anti-inflammatory therapy stated honestly as contested

›Intravitreal corticosteroid

›Not established as routine adjunct, evidence for benefit is mixed

›Ophthalmology-directed decision only after infection is being treated

›Systemic or topical corticosteroid

›Role in reducing inflammatory vision loss is debated

›Infection control takes priority over anti-inflammatory therapy

›Toxic anterior segment syndrome exception

›Topical corticosteroid is appropriate once infectious endophthalmitis has been excluded

›Do not treat with steroid alone until this distinction is made

Iatrogenic harms with routine ED interventions

›Routine intervention review for this patient

›Intubation

›Succinylcholine IV 1 to 1.5 mg/kg raises intraocular pressure and risks content extrusion if globe integrity is uncertain

›Verify against current pediatric guideline before use

›Rocuronium IV 0.6 to 1.2 mg/kg preferred when globe integrity concern exists

›Avoid in post-traumatic category with any open globe concern

›Sedation

›Ketamine effect on intraocular pressure is debated and agitation risk complicates a painful eye exam

›Propofol preferred when hemodynamics allow

›Fluid loading

›Standard sepsis resuscitation proceeds in endogenous disease with septic shock

›Monitor for volume overload in patients with endocarditis-associated heart failure

›Oxygen

›No specific ocular contraindication

›Treat hypoxemia per usual sepsis management

›Vasopressors

›Norepinephrine first-line for septic shock from endogenous source

›Titrate to mean arterial pressure target every 15 minutes

›No specific ocular contraindication

›Mechanical circulatory support

›Intra-aortic balloon pump or other support for endocarditis-associated cardiogenic shock requires anticoagulation that conflicts with a time-critical intraocular procedure

›Coordinate timing between cardiology and ophthalmology rather than delaying either intervention

›Anticoagulation

›Chronic anticoagulation or antiplatelet therapy is not routinely held for vitreous tap given its small-gauge, time-critical nature

›Hold or bridge when feasible for planned vitrectomy

›Fibrinolysis

›Thrombolysis for stroke thought secondary to septic emboli from endocarditis carries high hemorrhagic transformation risk from mycotic aneurysm or septic arteritis

›Flag for neurology and infectious diseases co-management before thrombolysis in this context, this is a way a standard stroke intervention kills this patient

›Analgesia

›Avoid high-dose NSAIDs before a planned intraocular procedure due to bleeding risk

›Opioids preferred, avoid oversedation that masks a worsening exam

Supportive care and analgesia

›Adjunctive measures

›Analgesia

›Acetaminophen IV or PO 1000 mg every 6 hours, maximum 4000 mg per day

›First-line for eye pain

›Opioid-sparing preference

›Hydromorphone IV 0.2 to 0.5 mg every 10 minutes titrated to comfort

›Reserved for severe breakthrough pain

›Respiratory and mental status monitoring

›Antiemesis

›Ondansetron IV 4 mg every 6 hours as needed

›Reduces Valsalva and secondary intraocular pressure spikes

›Maximum daily dose per local policy

›Glycemic control

›Hyperglycemia management in diabetic patients with endogenous source

›Blood glucose monitoring given lethargy risk in septic or elderly patients

09Special Populations/sp43

Pregnancy

›Pregnancy considerations

›Antibiotic safety

›Vancomycin and ceftazidime generally acceptable when systemic therapy needed

›Avoid aminoglycosides and tetracyclines when alternatives exist

›Intravitreal therapy

›Local intravitreal antibiotic doses are not significantly systemically absorbed

›Proceed without delay given time-critical vision threat

›Antifungal safety

›Fluconazole avoided in the first trimester when alternatives exist

›Amphotericin B preferred systemic antifungal in pregnancy when treatment cannot be deferred

›Obstetric coordination

›Maternal stabilization priority in endogenous sepsis

›Fetal monitoring in viable gestation if critically ill

Geriatric

›Geriatric considerations

›Higher exogenous case volume

›Cataract surgery prevalence

›Intravitreal injection prevalence for macular degeneration

›Anticoagulation and antiplatelet use

›Coordination before vitrectomy

›Bleeding risk with vitreous tap generally low but documented

›Medication safety

›Renal dosing adjustments for vancomycin and ceftazidime

›Polypharmacy interaction review

›Blunted presentation

›Reduced pain reporting

›Delayed recognition risk

10Background/b36

Epidemiology

›Incidence and organism patterns

›Post-cataract surgery incidence approximately 0.03% to 0.2% per procedure

›Most common exogenous category by absolute case volume

›Coagulase-negative staphylococci account for roughly two-thirds of culture-positive cases

›Post-intravitreal-injection incidence roughly 0.05% or less per injection

›Cumulative risk rises with repeated injection courses

›Similar organism profile to acute post-operative category

›Bleb-associated incidence

›Lower absolute incidence than post-cataract category

›Disproportionately higher rate of severe vision loss given organism virulence

›Endogenous endophthalmitis

›Accounts for roughly 2% to 8% of all endophthalmitis cases

›Rising incidence linked to intravenous drug use, indwelling catheters, and immunosuppression

›Higher mortality-linked significance because it signals systemic infection including endocarditis

Pathophysiology

›Mechanisms by category

›Exogenous inoculation

›Surgical or injection breach of the ocular surface barrier introduces organisms directly into the vitreous

›Bleb acts as a chronic portal of entry distinct from a single-event breach

›Hematogenous seeding in endogenous disease

›Blood-retinal and blood-ocular barrier breakdown during bacteremia or fungemia allows organism seeding

›Choroid seeded first with secondary vitreous extension

›Inflammatory cascade

›Neutrophilic response produces hypopyon and vitritis

›Toxin and enzyme-mediated retinal damage from virulent organisms

Therapeutic Considerations

›Why key treatments matter

11Patient Discharge Instructions/pdi22

copy discharge instructions

›Post-procedure instructions when stable for outpatient follow-up after ophthalmology-directed intravitreal therapy

›Medication adherence

›Topical antibiotic drops as adjunct exactly as directed

›Do not substitute drops for scheduled follow-up injection or procedure

›Activity restrictions

›Avoid rubbing or pressure on the eye

›Avoid swimming or contact lens use until cleared

›Follow-up plan

›Ophthalmology recheck within 24 to 48 hours

›Sooner recheck if any red flag develops

›Return immediately for red flags

›Worsening pain

›Worsening vision

›New or worsening hypopyon sensation or visible redness

›Fever

Why outpatient topical monotherapy is not appropriate

›Explicit patient and chart-facing statement

›Topical antibiotic drops alone do not treat endophthalmitis

›Do not achieve therapeutic intravitreal drug concentration

›Discharging a suspected case on drops alone is a recognized route to permanent vision loss

›Same-hour ophthalmology evaluation is required before any discharge decision

›Applies even when external exam appears mild

›Applies even when the patient requests discharge

12References/r17

Guidelines and key sources

›Professional guidance

›American Academy of Ophthalmology Preferred Practice Pattern on postoperative and bacterial endophthalmitis

›Emergent ophthalmology involvement emphasis

›Intravitreal antibiotic and vitrectomy decision framework

›Endophthalmitis Vitrectomy Study Group, Archives of Ophthalmology, 1995

›Visual acuity stratification for vitrectomy benefit

›Systemic antibiotic outcome findings

›American Heart Association guidance on infective endocarditis diagnosis and management

›Modified Duke criteria framework

›Echocardiography sequencing guidance

Evidence summaries

›Evidence and consensus framing

›Class I recommendation statements

›Emergent ophthalmology involvement whenever endophthalmitis is suspected

›Blood cultures and echocardiography whenever endogenous endophthalmitis is suspected

›Trial-derived practice points

›Vitrectomy benefit limited to presenting visual acuity of light perception only

›No added benefit from systemic antibiotics in exogenous postoperative disease

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.